Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASPIRIN PRIMARY PREVENTION DATA SHOW SMALL BUT SIGNIFICANT EFFECT: FURTHER TRIALS

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN PRIMARY PREVENTION DATA SHOW SMALL BUT SIGNIFICANT EFFECT: FURTHER TRIALS, however, are needed before daily aspirin use by healthy individuals can be recommended for prevention of primary vascular events, Richard Peto, Oxford University, et al., suggested in a large-scale, meta-analysis of data from 257 aspirin studies published in the Jan. 7 issue of the British Medical Journal. The study evaluates antiplatelet therapy, primarily aspirin, for three distinct groups: primary prevention; treatment for acute myocardial infarction and unstable angina; and for secondary prevention of myocardial infarction, angina, stroke, transient ischemic attack, arterial bypass surgery or angioplasty.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082320

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel